Back to Search
Start Over
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial
- Source :
- Expert Opinion on Investigational Drugs; October 2024, Vol. 33 Issue: 10 p1063-1074, 12p
- Publication Year :
- 2024
-
Abstract
- ABSTRACTObjectivesThis Phase 1 trial was planned to investigate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of a single dose of riliprubart in healthy East-Asian adult participants.MethodsA single-center, parallel-group, randomized, open-label, single-dose study was performed to evaluate the PK, PD, safety, and tolerability of riliprubart (50 mg/kg intravenous [IV] or 600 mg subcutaneous [SC]) in 37 healthy East-Asian (Chinese, Japanese, and Korean) participants.ResultsRiliprubart was slowly absorbed after SC administration (median tmax: 7.01–10.48 days) and showed a long half-life after IV or SC administration (mean: 9.52–11.0 weeks), with a bioavailability of 74.6% after SC administration. The PD profiles, which are evaluated by classical complement pathway activity or CH50, were similar and largely overlapped across East-Asian participants after a single IV or SC dose. Riliprubart was safe and well tolerated in participants following a single IV or SC dose.ConclusionsRiliprubart was safe and well tolerated and demonstrated favorable PK and PD profiles in healthy East-Asian participants following a single IV or SC dose. These results are comparable to first-in-human study results from non-East-Asian participants and support the same dosing regimen of riliprubart for global simultaneous clinical development.Clinical trial registrationThis trial is registered at https://cris.nih.go.kr(identifier: KCT0006571).
Details
- Language :
- English
- ISSN :
- 13543784 and 17447658
- Volume :
- 33
- Issue :
- 10
- Database :
- Supplemental Index
- Journal :
- Expert Opinion on Investigational Drugs
- Publication Type :
- Periodical
- Accession number :
- ejs67768697
- Full Text :
- https://doi.org/10.1080/13543784.2024.2394186